About eribulin mesylate
Microtubule inhibitor chemotherapy
Used for
- Treats unresectable or metastatic breast cancer after prior chemotherapy.
- Treats unresectable or metastatic liposarcoma after previous systemic treatment.
Usual adult dose
1.4 mg/m² intravenously over 2–5 minutes on days 1 and 8 of each 21-day cycle; dose adjustments may be needed.
Common side effects
- Low blood cell counts, including neutropenia and anemia
- Tiredness and weakness
- Nausea, constipation, or diarrhea
- Nerve damage causing numbness or tingling
Important warnings
- Can cause severe infections from low white blood cell counts.
- May cause prolonged QT heart rhythm changes; monitoring may be needed.
- Can cause serious nerve damage and fetal harm.
- Dose adjustments may be required for liver or kidney impairment.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for two weeks after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for two weeks after the final dose.
Interactions
- Medicines that prolong the QT interval may increase heart rhythm risks.
- Strong CYP3A4 inhibitors or inducers may alter eribulin exposure; clinical significance is uncertain.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.